NEXT ONCOLOGY Trademark of New Experimental Therapeutics of San Antonio
San Antonio-based South Texas Accelerated Research Therapeutics spreads
The San Antonio Partnership for Precision Therapeutics: A Billion
SwRI, Texas Biomed, UT Health San Antonio and UTSA launch new
Ryvu Therapeutics Presents Data on RVU120 at the San Antonio Breast
San Antonio’s Four Leading Research Institutions Join Together for
COMMENTS
Drug shows promise for treating brain tumors resulting from breast
Brenner, who also is clinical investigator for the Institute for Drug Development at UT Health San Antonio and co-leader of its Experimental and Development Therapeutics Program, is lead author of the trial's study published Aug. 7 in Nature Communications, titled, "Sacituzumab Govitecan in patients with breast cancer brain metastases and ...
NEXT Oncology
We will respond to you with more information soon. NEXT Oncology is your next option, the next breakthrough. NEXT Oncology strives to provide exceptional care, the latest cancer treatments, and a community devoted to finding a cure. We are transforming the industry through the development of the next breakthrough in cancer research.
Institute for Drug Development
Our contributions to the field include more than 20 FDA-approved new drugs (therapeutics), with many more in development. ... Experimental and Development Therapeutics Program; ... Our mission is to decrease the burden of cancer in San Antonio, South Texas and beyond. Make an appointment: (210) 450-1000 ...
About NEXT Oncology
He is dedicated to the advancement of new anticancer agents for patients whose current cancer therapy is no longer working to benefit them. Let NEXT Oncology be Your NEXT Option™ for the latest clinical trials of new agents and therapies. ... 2829 Babcock Road Suite 300, San Antonio, Texas 78229. Home. About NEXT Oncology. NEXT Oncology Team ...
Experimental/Developmental Therapeutics
The overall objective of the Experimental and Developmental Therapeutics Program is to discover, develop and test new and existing drugs. Our efforts give patients access to innovative care options close to home. Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, is a leading cancer center in Central and South Texas.
Clinical Trials
NEXT Oncology is dedicated to the advancement of Phase 1 cancer research through clinical trials of anticancer agents with the goal of providing innovative developments in cancer treatment. Clinical trials bridge the gap between research and effective cancer treatment. Clinical trials serve as the foundation of all cancer treatment and a chance ...
NCI Experimental Therapeutics (NExT)
What does the NExT Program provide? NExT provides resources for projects focused on developing therapies for unmet medical needs in the area of oncology that are not typically addressed by the private sector. NExT is NOT a grant mechanism.
Texas Oncology-San Antonio Babcock
2829 Babcock Road, Suite 300. San Antonio, TX 78229. T: 210-580-9500. F: 210-568-4577. Learn more about medical records.
San Antonio's four leading research institutions join together for
The new San Antonio Partnership for Precision Therapeutics (SA PPT) is being established by UT Health San Antonio, Texas Biomedical Research Institute (Texas Biomed), The University of Texas at San Antonio (UTSA) and Southwest Research Institute (SwRI ®). This groundbreaking initiative will leverage the unique bioscience capabilities of the ...
First-in-Human Study of the Ataxia Telangiectasia and Rad3 ...
Affiliations 1 University of Texas MD Anderson Cancer Center, Houston, Texas.; 2 New Experimental Therapeutics (NEXT), San Antonio, Texas.; 3 Newcastle University and Northern Centre for Cancer Care, Newcastle Hospitals NHS Trust, Newcastle Upon Tyne, United Kingdom.; 4 EMD Serono, Billerica, Massachusetts.; 5 The Healthcare Business of Merck KGaA, Darmstadt, Germany.
Program Guide
Of the efficacy-evaluable pts (n = 50), complete response (CR) or partial response (PR) was observed for 7/50 (14.0%), including 3 CR and 4 PR. Disease control (including CR, PR, or stable disease) was observed in 24/50 (48.0%). The median duration of response was 10 months (range = 4 to 32 months). Responses were observed in pts with prior ...
New Trials in Gynecologic Cancers: Could Your Patient Benefit?
Patients with these types of cancers are eligible for a phase 1/2 study of a new-concept targeted therapy called ELU-001. ... is hosted by New Experimental Therapeutics of San Antonio, which ...
The Evolution of Antibody-Drug Conjugates: A Positive ...
1 New Experimental Therapeutics (NEXT), San Antonio, TX. 2 Texas Oncology, San Antonio, TX. PMID: 32223669 DOI: 10.1200/EDBK_281103 Abstract In 2019, an important inflection point occurred when the U.S. Food and Drug Administration approved three new antibody-drug conjugates (ADCs) for the treatment of malignancies, including urothelial cancer ...
NEXT Oncology and MediLink Team Up on Phase 1 Clinical Trial
Contact: Lisa Owens, 210-601-6647. NEXT Oncology and MediLink Therapeutics Take "Team Approach" to. Next Level on Phase 1 First in Human Clinical Trial in San Antonio. (SAN ANTONIO, TX and CAMBRIDGE, MA) October 9, 2023 -- MediLink Therapeutics and NEXT Oncology are collaborating on a Phase 1 First in Human Clinical trial for an ...
DEVELOPMENTAL THERAPEUTICS
1Clinical Research,Texas Oncology-San Antonio Babcock NEXT Oncology, San Antonio, TX, USA; 2Investigational Cancer Therapeutics, ... advisory board memberships for Dr. Anthony Tolcher are paid to New Experimental Therapeutics, LLC d/b/a NEXT Oncology of which he is the CEO and Founder.: Adagene, Inc., ARO Biotherapeutics,
abstracts Immuno-Oncology and Technology
1NEXT Oncology, San Antonio, TX, USA; 2Oncology Department, Sarah Cannon ... advisory board memberships for Dr. Anthony Tolcher are paid to New Experimental Therapeutics, Llc d/b/a NEXT Oncology of which he is the CEO and Founder: Adagene, Inc., ARO Biotherapeutics,
ESMO Congress 2022
1 Clinical Research, Texas Oncology-San Antonio Babcock NEXT Oncology, 78229 - San Antonio/US; 2 Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 77035 - Houston/US; 3 Clinical Trials, Texas Oncology-Austin North NEXT Oncology, 78758 - Austin/US; 4 Medicine, Abramson Cancer Center, University of Pennsylvania, 19104 - Philadelphia/US
Drug shows promise for treating brain tumors
Brenner, who also is clinical investigator for the Institute for Drug Development at UT Health San Antonio and co-leader of its Experimental and Development Therapeutics Program, is lead author of ...
abstracts Annals of Oncology
New Experimental Therapeutics, LLC d/b/a NEXT Oncology of which Dr. Anthony Tolcher is CEO and Founder: ABL Bio Inc., Adagene Inc, ADC Therapeutics SA, Agenus Inc., Aminex Therapeutics, Inc., ... Belgium; 2Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan; 3Sarah Cannon Research Institute, Tennessee
New Experimental Therapeutics of San Antonio, Llc
Free and open company data on Texas (US) company NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO, LLC (company number 0802901445), 2829 BABCOCK RD STE 300, SAN ANTONIO, TX, 78229-6011. Changes to our website — to find out why access to some data now requires a login, click here. The Open Database Of The Corporate World.
News
NEXT Oncology and OncoBay Clinical Collaborate on Six Phase 1 Clinical Trials. April 23, 2024. FOR IMMEDIATE RELEASE DATE: April 22, 2024 Contact: Lisa Owens, 210-601-6647 (SAN ANTONIO, TX and RALEIGH, NC) April 22, 2024 --NEXT Oncology, a Phase 1 Clinical Trial organization with six ….
abstracts Annals of Oncology
1Investigational Cancer Therapeutics Dept. (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 2Clinical Research, New Experimental Therapeutics (NEXT), San Antonio, TX, USA; 3Newcastle University and Northern Centre for Cancer Care, Newcastle Hospitals Trust, Newcastle-upon-Tyne, Tyne and
A phase I study of highly potent oral ATR inhibitor (ATRi) tuvusertib
3018 Rapid Oral Abstract Session A phase I study of highly potent oral ATR inhibitor (ATRi) tuvusertib plus oral PARP inhibitor (PARPi) niraparib in patients with solid tumors.
IMAGES
COMMENTS
Brenner, who also is clinical investigator for the Institute for Drug Development at UT Health San Antonio and co-leader of its Experimental and Development Therapeutics Program, is lead author of the trial's study published Aug. 7 in Nature Communications, titled, "Sacituzumab Govitecan in patients with breast cancer brain metastases and ...
We will respond to you with more information soon. NEXT Oncology is your next option, the next breakthrough. NEXT Oncology strives to provide exceptional care, the latest cancer treatments, and a community devoted to finding a cure. We are transforming the industry through the development of the next breakthrough in cancer research.
Our contributions to the field include more than 20 FDA-approved new drugs (therapeutics), with many more in development. ... Experimental and Development Therapeutics Program; ... Our mission is to decrease the burden of cancer in San Antonio, South Texas and beyond. Make an appointment: (210) 450-1000 ...
He is dedicated to the advancement of new anticancer agents for patients whose current cancer therapy is no longer working to benefit them. Let NEXT Oncology be Your NEXT Option™ for the latest clinical trials of new agents and therapies. ... 2829 Babcock Road Suite 300, San Antonio, Texas 78229. Home. About NEXT Oncology. NEXT Oncology Team ...
The overall objective of the Experimental and Developmental Therapeutics Program is to discover, develop and test new and existing drugs. Our efforts give patients access to innovative care options close to home. Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, is a leading cancer center in Central and South Texas.
NEXT Oncology is dedicated to the advancement of Phase 1 cancer research through clinical trials of anticancer agents with the goal of providing innovative developments in cancer treatment. Clinical trials bridge the gap between research and effective cancer treatment. Clinical trials serve as the foundation of all cancer treatment and a chance ...
What does the NExT Program provide? NExT provides resources for projects focused on developing therapies for unmet medical needs in the area of oncology that are not typically addressed by the private sector. NExT is NOT a grant mechanism.
2829 Babcock Road, Suite 300. San Antonio, TX 78229. T: 210-580-9500. F: 210-568-4577. Learn more about medical records.
The new San Antonio Partnership for Precision Therapeutics (SA PPT) is being established by UT Health San Antonio, Texas Biomedical Research Institute (Texas Biomed), The University of Texas at San Antonio (UTSA) and Southwest Research Institute (SwRI ®). This groundbreaking initiative will leverage the unique bioscience capabilities of the ...
Affiliations 1 University of Texas MD Anderson Cancer Center, Houston, Texas.; 2 New Experimental Therapeutics (NEXT), San Antonio, Texas.; 3 Newcastle University and Northern Centre for Cancer Care, Newcastle Hospitals NHS Trust, Newcastle Upon Tyne, United Kingdom.; 4 EMD Serono, Billerica, Massachusetts.; 5 The Healthcare Business of Merck KGaA, Darmstadt, Germany.
Of the efficacy-evaluable pts (n = 50), complete response (CR) or partial response (PR) was observed for 7/50 (14.0%), including 3 CR and 4 PR. Disease control (including CR, PR, or stable disease) was observed in 24/50 (48.0%). The median duration of response was 10 months (range = 4 to 32 months). Responses were observed in pts with prior ...
Patients with these types of cancers are eligible for a phase 1/2 study of a new-concept targeted therapy called ELU-001. ... is hosted by New Experimental Therapeutics of San Antonio, which ...
1 New Experimental Therapeutics (NEXT), San Antonio, TX. 2 Texas Oncology, San Antonio, TX. PMID: 32223669 DOI: 10.1200/EDBK_281103 Abstract In 2019, an important inflection point occurred when the U.S. Food and Drug Administration approved three new antibody-drug conjugates (ADCs) for the treatment of malignancies, including urothelial cancer ...
Contact: Lisa Owens, 210-601-6647. NEXT Oncology and MediLink Therapeutics Take "Team Approach" to. Next Level on Phase 1 First in Human Clinical Trial in San Antonio. (SAN ANTONIO, TX and CAMBRIDGE, MA) October 9, 2023 -- MediLink Therapeutics and NEXT Oncology are collaborating on a Phase 1 First in Human Clinical trial for an ...
1Clinical Research,Texas Oncology-San Antonio Babcock NEXT Oncology, San Antonio, TX, USA; 2Investigational Cancer Therapeutics, ... advisory board memberships for Dr. Anthony Tolcher are paid to New Experimental Therapeutics, LLC d/b/a NEXT Oncology of which he is the CEO and Founder.: Adagene, Inc., ARO Biotherapeutics,
1NEXT Oncology, San Antonio, TX, USA; 2Oncology Department, Sarah Cannon ... advisory board memberships for Dr. Anthony Tolcher are paid to New Experimental Therapeutics, Llc d/b/a NEXT Oncology of which he is the CEO and Founder: Adagene, Inc., ARO Biotherapeutics,
1 Clinical Research, Texas Oncology-San Antonio Babcock NEXT Oncology, 78229 - San Antonio/US; 2 Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 77035 - Houston/US; 3 Clinical Trials, Texas Oncology-Austin North NEXT Oncology, 78758 - Austin/US; 4 Medicine, Abramson Cancer Center, University of Pennsylvania, 19104 - Philadelphia/US
Brenner, who also is clinical investigator for the Institute for Drug Development at UT Health San Antonio and co-leader of its Experimental and Development Therapeutics Program, is lead author of ...
New Experimental Therapeutics, LLC d/b/a NEXT Oncology of which Dr. Anthony Tolcher is CEO and Founder: ABL Bio Inc., Adagene Inc, ADC Therapeutics SA, Agenus Inc., Aminex Therapeutics, Inc., ... Belgium; 2Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan; 3Sarah Cannon Research Institute, Tennessee
Free and open company data on Texas (US) company NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO, LLC (company number 0802901445), 2829 BABCOCK RD STE 300, SAN ANTONIO, TX, 78229-6011. Changes to our website — to find out why access to some data now requires a login, click here. The Open Database Of The Corporate World.
NEXT Oncology and OncoBay Clinical Collaborate on Six Phase 1 Clinical Trials. April 23, 2024. FOR IMMEDIATE RELEASE DATE: April 22, 2024 Contact: Lisa Owens, 210-601-6647 (SAN ANTONIO, TX and RALEIGH, NC) April 22, 2024 --NEXT Oncology, a Phase 1 Clinical Trial organization with six ….
1Investigational Cancer Therapeutics Dept. (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 2Clinical Research, New Experimental Therapeutics (NEXT), San Antonio, TX, USA; 3Newcastle University and Northern Centre for Cancer Care, Newcastle Hospitals Trust, Newcastle-upon-Tyne, Tyne and
3018 Rapid Oral Abstract Session A phase I study of highly potent oral ATR inhibitor (ATRi) tuvusertib plus oral PARP inhibitor (PARPi) niraparib in patients with solid tumors.